Want to see ASMB full AI Analyst Report?
Top Page
Assembly Biosciences
(NASDAQ:ASMB)
Select Model
Select Model
Rating:50Neutral
Price Target:
$23.00
▼(-34.90% Downside)
Action:Reiterated
Date:09/16/26
The score is driven primarily by mixed financial performance: a very strong, low-leverage balance sheet and sharply improved income statement are offset by continued, material cash burn. Technicals add meaningful downside pressure given the clear downtrend versus major moving averages and weak momentum readings. Valuation is also a headwind due to a high P/E and no dividend yield provided.
Positive Factors
Revenue Scale and Gross Margin
Revenue has scaled sharply from prior years while maintaining a strong gross margin, indicating meaningful economic value in the company’s current activities. If this revenue base persists, it can provide greater capacity to support research investment and improve operating leverage as development programs advance.
Negative Factors
Persistent Cash Burn
Materially negative operating and free cash flow shows that the business is not yet self-funding its activities. Continued cash burn can consume financial resources needed for clinical development and may eventually require additional financing, even with a strong balance sheet and near-breakeven net income.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Scale and Gross Margin
Revenue has scaled sharply from prior years while maintaining a strong gross margin, indicating meaningful economic value in the company’s current activities. If this revenue base persists, it can provide greater capacity to support research investment and improve operating leverage as development programs advance.
Read all positive factors
Assembly Biosciences (ASMB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$463.61M
Dividend YieldN/A
Average Volume (3M)338.70K
Price to Earnings (P/E)37.0
Beta (1Y)1.40
Revenue Growth125.12%
EPS Growth98.69%
CountryUS
Employees73
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.55
Shares Outstanding20,360,596
10 Day Avg. Volume252,831
30 Day Avg. Volume338,702
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)1.84
Price to Sales (P/S)5.27
P/FCF Ratio-9.26
Enterprise Value/Market Cap0.43
Enterprise Value/Revenue2.67
Enterprise Value/Gross Profit3.44
Enterprise Value/Ebitda2.94K
Forecast
1Y Price Target
$49.50Price Target Upside40.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.15
Revenue Forecast (FY)$52.01M
Assembly Biosciences Business Overview & Revenue Model
Company Description
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candida...
Assembly Biosciences Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
83
Very Positive
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 74.84M | 72.30M | 28.52M | 7.16M | 0.00 | 6.25M |
| Gross Profit | 58.18M | 72.17M | -27.41M | -41.74M | -69.08M | 6.25M |
| EBITDA | 68.00K | -5.99M | -39.72M | -60.74M | -92.52M | -90.58M |
| Net Income | -42.00K | -6.12M | -40.18M | -61.23M | -93.09M | -129.85M |
Balance Sheet | ||||||
| Total Assets | 330.83M | 257.59M | 119.17M | 136.82M | 101.79M | 191.06M |
| Cash, Cash Equivalents and Short-Term Investments | 320.36M | 248.11M | 112.08M | 130.25M | 91.61M | 146.63M |
| Total Debt | 2.35M | 2.63M | 3.09M | 2.34M | 3.46M | 6.48M |
| Total Liabilities | 25.18M | 50.84M | 85.81M | 95.73M | 19.13M | 22.13M |
| Stockholders Equity | 305.65M | 206.75M | 33.36M | 41.10M | 82.66M | 168.93M |
Cash Flow | ||||||
| Free Cash Flow | -38.57M | -41.16M | -51.15M | 22.49M | -84.56M | -96.49M |
| Operating Cash Flow | -38.48M | -41.09M | -51.12M | 22.74M | -84.46M | -93.40M |
| Investing Cash Flow | -234.51M | -113.47M | 40.17M | -69.14M | 90.64M | 26.52M |
| Financing Cash Flow | 281.27M | 174.67M | 29.45M | 13.82M | 614.00K | 53.06M |
Assembly Biosciences Technical Analysis
Negative
35.33
Price Trends
28.44
Negative
27.14
Negative
27.97
Negative
Market Momentum
-1.93
Negative
25.87
Positive
44.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASMB, the sentiment is Negative. The current price of 35.33 is above the 20-day moving average (MA) of 23.57, above the 50-day MA of 28.44, and above the 200-day MA of 27.97, indicating a bearish trend. The MACD of -1.93 indicates Negative momentum. The RSI at 25.87 is Positive, neither overbought nor oversold. The STOCH value of 44.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ASMB.
Assembly Biosciences Risk Analysis
Assembly Biosciences disclosed 30 risk factors in its most recent earnings report. Assembly Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Assembly Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $750.73M | -3.30 | -106.15% | ― | ― | 10.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $463.61M | 36.98 | -0.02% | ― | 125.12% | 98.69% | |
48 Neutral | $297.68M | -3.04 | -47.12% | ― | -52.96% | 30.51% | |
48 Neutral | $249.55M | -2.38 | -41.85% | ― | ― | 64.51% | |
45 Neutral | $316.39M | -8.81 | -28.41% | 0.12% | ― | 14.04% | |
41 Neutral | $1.17B | -0.06 | -91.63% | ― | ― | 69.48% |
* Healthcare Sector Average
ASMB
Assembly Biosciences
20.34
-8.05
-28.36%
BNTC
Benitec Biopharma
8.63
-6.43
-42.70%
ANNX
Annexon Biosciences
3.83
0.83
27.67%
QSI
Quantum-Si
1.41
-0.74
-34.42%
VOR
Vor Biopharma
19.06
-11.75
-38.14%
LXEO
Lexeo Therapeutics, Inc.
2.74
-5.76
-67.76%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.